Orthofix Medical (NASDAQ:OFIX) Releases Quarterly Earnings Results, Beats Expectations By $0.11 EPS

Posted by Brenda Bartman on Nov 9th, 2026

Orthofix Medical (NASDAQ:OFIX – Get Free Report) issued its quarterly earnings data on Monday. The medical device company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.11, Zacks reports. The firm had revenue of $207.86 million during the quarter, compared to analyst estimates of $210.52 million. Orthofix Medical had a negative return on equity of 14.05% and a negative net margin of 7.41%.

Here are the key takeaways from Orthofix Medical’s conference call:

Third-quarter results were below expectations: U.S. spine fixation sales fell 5%, affected by market softness, supplier delays and instrument-set constraints. Orthofix lowered its 2026 outlook to $825–$830 million in net sales and $86–$88 million in adjusted EBITDA.
Results were stronger in other businesses: Limb Reconstruction sales rose 9% and Therapeutic Solutions sales increased 4%; U.S. biologics was roughly flat sequentially, and management said it returned to year-over-year growth in October. Adjusted EBITDA rose to $26 million from $24.6 million a year earlier, despite lower spine revenue.
Management is concentrating spine resources on core distributors, which generate about 80% of U.S. spinal implant revenue, and said supplier fixes are underway. It expects the VIRATA open-procedure system to launch in the fourth quarter and views the business as better positioned for 2027, though the recovery is expected to take time.
Orthofix expects an approximately $22 million spine sales headwind in 2027 from European MDR requirements. A European distributor arrangement is expected to add about $15 million to 2026 sales, mostly in Q4, but creates a temporary cash-timing headwind because related cash receipts are expected in 2027.

Orthofix Medical Stock Performance

Shares of OFIX stock opened at $7.90 on Tuesday. Orthofix Medical has a 12 month low of $6.52 and a 12 month high of $16.42. The company’s fifty day moving average price is $9.25 and its 200-day moving average price is $10.96. The company has a current ratio of 2.84, a quick ratio of 1.67 and a debt-to-equity ratio of 0.55. The stock has a market cap of $321.77 million, a PE ratio of -5.13 and a beta of 0.66.

Analysts Set New Price Targets

Several research firms have weighed in on OFIX. Weiss Ratings lowered Orthofix Medical from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, November 3rd. Canaccord Genuity Group lowered their target price on shares of Orthofix Medical from $18.00 to $13.00 and set a “buy” rating on the stock in a report on Monday, August 10th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $14.75.

Check Out Our Latest Research Report on OFIX

Trending Headlines about Orthofix Medical

Here are the key news stories impacting Orthofix Medical this week:

Positive Sentiment: Orthofix reported Q3 earnings of $0.18 per share, above the Zacks consensus estimate of $0.11. Its quarterly loss also declined year over year. Orthofix Surpasses Q3 Earnings Estimates
Negative Sentiment: Q3 revenue was $207.86 million, below the $210.52 million consensus estimate, indicating sales came in short of expectations. Orthofix Reports Third-Quarter Results
Negative Sentiment: The company lowered its 2026 net sales outlook to $825 million–$830 million, below the roughly $851 million analyst consensus. The guidance cut, announced amid accelerated U.S. spine actions, may weigh on expectations for near-term growth. Orthofix Revises 2026 Sales Outlook

About Orthofix Medical

(Get Free Report)

Orthofix Medical Inc is a medical device company focused on spinal and orthopedic solutions. The company develops, manufactures and distributes products designed to help treat spinal disorders, support bone healing and address orthopedic trauma and related musculoskeletal conditions.

Its product portfolio includes spinal fixation and interbody systems, biologics and bone-grafting products, bone growth stimulation devices, and technologies for spinal motion preservation and deformity correction.